期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 131, 期 2, 页码 339-345出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.10.013
关键词
Asthma; chemoattractant receptor homologous molecule expressed on T(H)2 cells; D-prostanoid; Asthma Control Questionnaire; prostaglandin D-2
资金
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases
- NIH/National Heart, Lung, and Blood Institute
- Amgen
- GlaxoSmithKline
- MedImmune
- Sanofi Aventis
Background: The D-prostanoid receptor and the chemoattractant receptor homologous molecule expressed on T(H)2 cells (CRTH2) are implicated in asthma pathogenesis. AMG 853 is a potent, selective, orally bioavailable, small-molecule dual antagonist of human D-prostanoid and CRTH2. Objective: We sought to determine the efficacy and safety of AMG 853 compared with placebo in patients with inadequately controlled asthma. Methods: Adults with moderate-to-severe asthma were randomized to placebo; 5, 25, or 100 mg of oral AMG 853 twice daily; or 200 mg of AMG 853 once daily for 12 weeks. All patients continued their inhaled corticosteroids. Long-acting beta-agonists were not allowed during the treatment period. Allowed concomitant medications included short-acting beta-agonists and a systemic corticosteroid burst for asthma exacerbation. The primary end point was change in total Asthma Control Questionnaire score from baseline to week 12. Secondary and exploratory end points included FEV1, symptom scores, rescue short-acting beta-agonist use, and exacerbations. Results: Among treated patients, no effect over placebo (n = 79) was observed in mean changes in Asthma Control Questionnaire scores at 12 weeks (placebo, -0.492; range for AMG 853 groups [n = 317], -0.444 to -0.555). No significant differences between the active and placebo groups were observed for secondary end points. The most commonly reported adverse events were asthma, upper respiratory tract infection, and headache; 9 patients experienced serious adverse events, all of which were deemed unrelated to study treatment by the investigator. Conclusion: AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma. (J Allergy Clin Immunol 2013;131:339-45.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据